219 related articles for article (PubMed ID: 18380993)
1. Effects of niacin on glucose control in patients with dyslipidemia.
Goldberg RB; Jacobson TA
Mayo Clin Proc; 2008 Apr; 83(4):470-8. PubMed ID: 18380993
[TBL] [Abstract][Full Text] [Related]
2. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
3. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
4. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
5. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
6. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
7. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
Sazonov V; Maccubbin D; Sisk CM; Canner PL
Int J Clin Pract; 2013 Apr; 67(4):297-302. PubMed ID: 23521322
[TBL] [Abstract][Full Text] [Related]
8. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
Mason CM; Doneen AL
J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
[TBL] [Abstract][Full Text] [Related]
9. Combination lipid therapy in type 2 diabetes mellitus.
Vergès B
Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
McKenney JM
Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
[TBL] [Abstract][Full Text] [Related]
11. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
12. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
13. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
[TBL] [Abstract][Full Text] [Related]
14. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA
JAMA; 2000 Sep; 284(10):1263-70. PubMed ID: 10979113
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
17. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
Keenan JM
J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
19. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
20. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
